Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0AW4X
|
||||
| Former ID |
DNC013348
|
||||
| Drug Name |
N-(1-(3-bromobenzyl)piperidin-4-yl)-1-naphthamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H23BrN2O
|
||||
| Canonical SMILES |
C1CN(CCC1NC(=O)C2=CC=CC3=CC=CC=C32)CC4=CC(=CC=C4)Br
|
||||
| InChI |
1S/C23H23BrN2O/c24-19-8-3-5-17(15-19)16-26-13-11-20(12-14-26)25-23(27)22-10-4-7-18-6-1-2-9-21(18)22/h1-10,15,20H,11-14,16H2,(H,25,27)
|
||||
| InChIKey |
USZMCEOIEOTIGM-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2A receptor | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | 5HT2 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2007 Mar 15;17(6):1570-4. Epub 2007 Jan 8.Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the affinity for D2L, D4.2, and 5-HT2A receptors. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.